{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-084444","form_type":"8-K","ticker":"RLYB","cik":"0001739410","company_name":"Rallybio Corp","filed_at":"2026-03-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.045579+00:00","generated_at":"2026-05-15T22:41:52.386123+00:00","sec_items":["1.01","3.02","5.01","5.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Rallybio agrees to reverse merger with Candid; Rallybio holders get ~3.65% of combined firm","bullets":["Rallybio pre-merger holders expected to own ~3.65% of combined company; Candid holders ~57.55%; financing investors ~38.80% (based on $505.5M raise).","Concurrent $505.5M private placement from accredited investors, shares convert to Rallybio common at closing.","Post-merger CEO will be Ken Song, current Candid Chairman/President/CEO; current Rallybio executives to resign.","Rallybio regained Nasdaq $1.00 bid compliance after 1-for-8 reverse stock split effective Feb 6, 2026.","Rallybio stockholders must approve share issuance (>20%), reverse split, name change to 'Candid Therapeutics, Inc.'"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-084444","json":"https://secwatch.observer/filing/0001193125-26-084444.json","markdown":"https://secwatch.observer/filing/0001193125-26-084444.md","text":"https://secwatch.observer/filing/0001193125-26-084444.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739410/000119312526084444/0001193125-26-084444-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739410/000119312526084444/d108429d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T22:41:52.386123+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"69184b6378a2d470105f3ff76aca2c0967e0addc","claim":"Rallybio Corp entered into Agreement and Plan of Merger and Reorganization with Candid Therapeutics, Inc. (effective 2026-03-01).","evidence_excerpt":"On March 1, 2026, Rallybio Corporation, a Delaware corporation (“ Rallybio ”), entered into an Agreement and Plan of Merger and Reorganization (the “ Merger Agreement ”) with Candid Therapeutics, Inc., a Delaware corporation (“ Candid ”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1739410/000119312526084444/0001193125-26-084444-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Candid Therapeutics, Inc."},{"label":"Effective","value":"2026-03-01"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}